SEC Form 4 · accession 0001209191-17-038426
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberly J Popovits
Officer — President and CEO · Director
Period of report
Jun 5, 2017
Accepted (ET)
Jun 7, 2017 · 7:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 5, 2017 | M | 5,000 | $17.33 | A | 84,057 | D | |
| Common StockF2,F3,F4,F1 | Jun 5, 2017 | S | 5,000 | $32.3164 | D | 79,057 | D | |
| Common Stock | Jun 5, 2017 | G | 100 | $0.00 | D | 199,387 | I | Held by the Popovits 2010 Trust |
| Common Stock | holding | — | — | — | 16,825 | I | Held in trust for the benefit of Ms. Popovits' son, of which Ms. Popovits is trustee. | |
| Common Stock | holding | — | — | — | 12,298 | I | Held by Morgan Stanley as Custodian for Benefit of Kimberly Popovits |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F5 | $17.33 | Jun 5, 2017 | M | 5,000 | D | — | Dec 4, 2018 | Common Stock | 0 | 47,900 | D |
Explanation of responses
- F1Includes an aggregate of 45,294 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 6, 2016.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $32.08 to $32.73.
- F5The option became exercisable as to 25% of the shares on December 4, 2009, and became exercisable as to 1/48th of the shares each full month thereafter.